Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect [TheStreet.com]
Caris Life Sciences, Inc. (CAI)
Last caris life sciences, inc. earnings: 10/29 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.capps.com/investor-relations
Company Research
Source: TheStreet.com
Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approaches IRVING, Texas March 31, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the finalized Achieve 1 Study results. These results represent a major milestone in Caris' goal to detect cancer earlier, through the future launch of Caris Detect™, its multi-cancer early detection (MCED) test. Caris Detect leverages Caris' industry-leading molecular profiling data, which has processed more than 1 million cases and generated more than 50 billion molecular markers. This deep molecular foundation enables Caris' AI models to identify, with unprecedented resolution, difficult-to-detect biological signals associated with early-stage cancers. The Achieve 1 Study systematically assessed Caris Detect's diagnostic accuracy across a heterogeneous patient cohort, quantifying its
Show less
Read more
Impact Snapshot
Event Time:
CAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAI alerts
High impacting Caris Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
CAI
News
- Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies [Yahoo! Finance]Yahoo! Finance
- Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies [TheStreet.com]TheStreet.com
- Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid MalignanciesPR Newswire
- Caris Life Sciences (CAI) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating and a $27.00 price target on the stock.MarketBeat
- Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect [Yahoo! Finance]Yahoo! Finance
CAI
Earnings
- 2/26/26 - Beat
CAI
Sec Filings
- 4/2/26 - Form 8-K
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- CAI's page on the SEC website